4.7 Letter

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Journal

BIOMARKER RESEARCH
Volume 9, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40364-021-00343-3

Keywords

Relapsed/refractory B-cell precursor acute lymphoblastic leukemia; Adult B-cell lymphoma/leukemia; Targeted treatment; Chemotherapy regimen; Daratumumab; CD38; venetoclax; Bcl-2; Refractory disease; Immunotherapies

Ask authors/readers for more resources

Patients with relapsed/refractory B-ALL often have poor prognosis, requiring a complete molecular response for long-term survival, with immunotherapies being the main effective treatments. However, treatment options are limited when lymphoblasts do not express immunotherapeutic targets.
Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell transplantation. Immunotherapies targeting CD19, CD20, or CD22 are very efficient in achieving this goal. However, in the absence of the expression of these immunotherapeutic targets by lymphoblasts, treatment options are extremely scarce. We report the successful treatment of a 26-year-old man who suffered R/R, CD19, CD20, and CD22 negative B-ALL targeting Bcl-2 and CD38 by combining venetoclax and daratumumab with chemotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available